Pharming (PHAR) Common Equity (2019 - 2026)
Pharming's (PHAR) quarterly Common Equity came in at $270.5 million in Q2 2026, up 12.92% YoY from $239.6 million in Q2 2025, and up 0.57% on a QoQ basis from $269.0 million in Q1 2026.
Pharming (PHAR) Common Equity (2019 - 2026) Analysis & Trends
Pharming (PHAR) has 8 years of Common Equity data on file, last reported at $270.5 million in Q2 2026.
- Quarterly Common Equity rose 12.92% year-over-year to $270.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $270.5 million (up 12.92% YoY) and the FY2025 annual result came in at $277.1 million, up 25.35% from the prior year.
- Common Equity improved to $270.5 million in Q2 2026, from $269.0 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $270.5 million in Q2 2026 to a low of -$0.02 in Q4 2025.
- A 5-year average of $197.8 million and a median of $212.6 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity jumped 104995.39% — and 2025, when it plunged 100.0%.
- Tracing PHAR's Common Equity over 5 years: stood at $204.6 million in 2022, then grew by 6.91% to $218.8 million in 2023, then advanced by 1.04% to $221.1 million in 2024, then sank by 100.0% to -$0.02 in 2025, then soared by 1803266666766.67% to $270.5 million in 2026.
- The last three Common Equity figures came in at $270.5 million (Q2 2026), $269.0 million (Q1 2026), and -$0.02 (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Pharming | 824.47 Mn | 666.19 Mn | 141.47 Mn | 270.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 270.49 Mn |
| Mar 31, 2026 | 268.96 Mn |
| Dec 31, 2025 | -0.02 |
| Sep 30, 2025 | 264.64 Mn |
| Jun 30, 2025 | 239.55 Mn |
| Mar 31, 2025 | 215.29 Mn |
| Dec 31, 2024 | 221.06 Mn |
| Sep 30, 2024 | 225.79 Mn |
| Jun 30, 2024 | 220.94 Mn |
| Mar 31, 2024 | 205.95 Mn |
| Dec 31, 2023 | 218.78 Mn |
| Sep 30, 2023 | 209.94 Mn |
| Jun 30, 2023 | 200.37 Mn |
| Mar 31, 2023 | 199.34 Mn |
| Dec 31, 2022 | 204.64 Mn |
| Sep 30, 2022 | 200,254.00 |
| Jun 30, 2022 | 199.67 Mn |
| Mar 31, 2022 | 194.02 Mn |
| Dec 31, 2021 | 194,716.44 |
| Sep 30, 2021 | 193.55 Mn |